Japanese medical technology company will introduce U.S. surgeons and industry partners to its
DuraBeam® and PeriBeam® devices
WASHINGTON, Sept. 27, 2026 (GLOBE NEWSWIRE) —
TamaBio Company Limited, a Japanese
medical technology company developing synthetic biomembranes and regenerative medical
devices, will exhibit at the American College of Surgeons Clinical Congress 2026, taking place
September 26–29 in Washington, D.C.
During the conference, TamaBio will introduce surgeons, researchers, medical device companies
and potential distribution partners to its ion-beam-processed expanded polytetrauoroethylene, or
ePTFE, biomembrane platform. The technology underpins the company’s DuraBeam® dura mater
substitute and PeriBeam® pericardial membrane.
TamaBio developed its biomembrane platform to address persistent challenges associated with
implanted surgical materials, including tissue adhesion, calcication, infection and uid leakage. Its
exible, biocompatible membranes are designed to support tissue repair following implantation
while serving as substitutes for damaged or missing anatomical membranes.
“ACS Clinical Congress is an important opportunity to introduce our synthetic biomembrane
technology to surgeons who understand the challenges associated with implantable materials in
clinical practice,” said Tetsuya Nagao, Managing Director and CEO of TamaBio. “Our goal is to
develop highly biocompatible medical devices that can replace damaged membranes while
supporting the body’s own tissue-repair process. By engaging with U.S. surgeons, researchers and
industry partners in Washington, we hope to advance the clinical collaboration needed to bring
Japanese medical innovation to more patients worldwide.”
TamaBio reports that its synthetic biomembranes have been used in thousands of surgical
procedures. DuraBeam and PeriBeam have received Class IV medical device manufacturing and
marketing approval from Japan’s Ministry of Health, Labour and Welfare. The company has also
secured foundational patents in Japan, the United States, China and Taiwan.
PeriBeam is intended for pericardial replacement and substitution in cardiac surgery. In December
2025, TamaBio announced that the FDA-listed device, manufactured at the company’s FDA-
registered establishment, had been exported to the United States for clinical surgical use.
DuraBeam is designed for dura mater replacement and substitution in neurosurgical procedures.
Beyond its commercial products, TamaBio is advancing a regenerative medicine pipeline that
includes articial blood vessels and experimental sheets for nerve, brain and spinal cord injury
repair. The company is collaborating with Tohoku University to investigate the potential of synthetic
biomembrane implantation to support neurological function recovery following brain contusion,
spinal cord injury and cerebral infarction.
TamaBio will participate in the ACS Clinical Congress Exhibit Hall from September 27–29. Nagao will
be available in Washington, D.C., from September 25–30 for media interviews, industry briengs and
partnership discussions.
To request an interview or schedule a meeting with Tetsuya Nagao, contact:
Ronjini Joshua
Media Relations for TamaBio.
ronjini.joshua@aumaudvisors.com
949- 295-9779
About TamaBio Company Limited
Founded in Tokyo in 2016, TamaBio Company Limited develops, manufactures and commercializes
synthetic biomembranes, regenerative medical devices and other advanced medical technologies.
The company’s platform is based on specialized polymer-processing technology originating from
RIKEN, Japan’s national research and development agency. TamaBio’s products include
DuraBeam®, a synthetic dura mater substitute, and PeriBeam®, a synthetic pericardial membrane.
The company is also developing technologies for articial blood vessels, the repair of nerve, brain
and spinal cord injuries, and the treatment of myocardial infarction. For more information, visit
https://tamabio.com/en/.